Skip to main content
. 2015 Sep 5;6(31):31313–31322. doi: 10.18632/oncotarget.5182

Figure 1. Effect of ibrutinib on EGFR wt/mutant NSCLCs.

Figure 1

a. Ibrutinib effects on wt EGFR and mutant EGFR- mediated signaling pathways; b. Ibrutinib selectively arrests mutant EGFR-expressing NSCLC cell lines in G0/G1 phase. c. Ibrutinib selectively induces apoptosis in EGFR mutant-expressing NSCLC cell lines.